Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei-Lin Wang

Showing results (261-270 of 263) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 263 results.
Communications Medicine|May 30, 2026
Proxied therapeutic inhibition on sclerostin and atrial fibrillation riskYu Qian, Peng-Lin Guan, Jingyan Hu, et al.
Cancer Medicine|September 20, 2022
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II studyGuo-Ming Shi, Xiao-Yong Huang, Tian-Fu Wen, et al.
Liver Cancer|October 16, 2018
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)Jian Zhou, Hui-Chuan Sun, Zheng Wang, et al.
Pageof 27

Showing results (261-270 of 263) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 263 results.
Communications Medicine|May 30, 2026
Proxied therapeutic inhibition on sclerostin and atrial fibrillation riskYu Qian, Peng-Lin Guan, Jingyan Hu, et al.
Cancer Medicine|September 20, 2022
Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II studyGuo-Ming Shi, Xiao-Yong Huang, Tian-Fu Wen, et al.
Liver Cancer|October 16, 2018
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)Jian Zhou, Hui-Chuan Sun, Zheng Wang, et al.
Pageof 27